EMS S.A. : Company Profile and SWOT Analysis

  • June 2012
  • -
  • World Market Intelligence Ltd
  • -
  • 13 pages

Synopsis

World Market Intelligence's 'EMS S.A. : Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key competitors, key facts, key employees, location and subsidiaries as well as information on products and services.

Summary

This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.

WMI's 'EMS S.A. : Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.

WMI strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Scope

• Examines and identifies key information and issues about 'EMS S.A.' for business intelligence requirements
• Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
• The profile also contains information on business operations, company history, major products and services, key employees


Reasons To Buy

• Quickly enhance your understanding of the company
• Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
• Recognize potential partnerships and suppliers


Key Highlights

EMS S.A. (EMS) is a pharmaceutical company, which is focused in the development of products for improvement of health and well being of the population. EMS operates two industrial plants in Sao Bernardo do Campo and Hortolandia, Sao Paulo. EMS has a portfolio of over 1,400 products. EMS product offering includes antianemics, analgesics, antibiotics, anti-inflammatories, antihypertensive, immunosuppressants and contraceptives. In addition, the company sells 27 products to hospitals, clinics and health agencies. EMS is ISO 9001 and ISO 140001 certified. The company is focused on the research and development (R&D) activities to develop benzodiazepines diazepam, lorazepam and bromazepam sedative drugs and neurological products. EMS is headquartered in Hortolandia, Brazil.

Table Of Contents

Table of Contents

1 Business Analysis
1.1 Company Overview
1.2 Business Description
1.3 Major Products and Services
2 SWOT Analysis
2.1 SWOT Analysis - Overview
2.2 Strengths
2.3 Weaknesses
2.4 Opportunities
2.5 Threats
3 Company Statement
4 History
5 Key Employees
6 Locations and Subsidiaries
6.1 Head Office
6.2 Other Locations and Subsidiaries
7 Appendix
7.1 Methodology
7.2 Disclaimer




List of Tables

Table 1: Major Products and Services
Table 2: History
Table 3: Key Employees
Table 4: Subsidiaries


















View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Nicotine Addiction - Pipeline Review, H1 2014

Nicotine Addiction - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Nicotine Addiction - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Nicotine Addiction - Pipeline Review, H1 2014', provides an overview of the Nicotine Addiction's therapeutic pipeline. ...

Opioid Induced Side Effects - Pipeline Review, H1 2014

Opioid Induced Side Effects - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Opioid Induced Side Effects - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Opioid Induced Side Effects - Pipeline Review, H1 2014', provides an overview of the Opioid Induced Side Effects's ...

Post-Operative Pain - Pipeline Review, H1 2014

Post-Operative Pain - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Post-Operative Pain - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Post-Operative Pain - Pipeline Review, H1 2014', provides an overview of the Post-Operative Pain's therapeutic pipeline. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.